store at low temperature,store under nitrogen,keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Dapagliflozin [461432-26-8]
Referência T2389-25mg
Tamanho : 25mg
Marca : TargetMol
Contactar o distribuidor local :
Telefone : +1 850 650 7790
Dapagliflozin
Catalog No. T2389 CAS 461432-26-8
Synonyms: BMS-512148
Dapagliflozin (BMS-512148) is a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity.
All TargetMol products are for research or drug registration purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose in violation of laws and regulations.
Dapagliflozin, CAS 461432-26-8
| Description | Dapagliflozin (BMS-512148) is a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity. |
| Targets&IC50 | SGLT2 (human):1.1 nM(EC50) |
| Cell Research | To perform the cell survival assay, cells are collected after 24 h incubation with vehicle or dapagliflozin pretreatment in 30-min ischemia and surviving cells are counted with Trypan blue staining. The percentage survival is determined by quantization of the relative viable number of treated cells divided by the viable number of untreated cells. |
| Synonyms | BMS-512148 |
| Molecular Weight | 408.87 |
| Formula | C21H25ClO6 |
| CAS No. | 461432-26-8 |
Storage
Solubility Information
Ethanol: 14 mg/mL (34.2 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 45 mg/mL (110.06 mM)
References and Literature
1. Meng W, et al. J Med Chem, 2008, 51(5), 1145-1149. 2. Han S, et al. Diabetes, 2008, 57(6), 1723-1729. 3. Obermeier M, et al. Drug Metab Dispos, 2010, 38(3), 405-414. 4. Macdonald FR, et al. Diabetes Obes Metab, 2010, 12(11), 12004-12012. 5. Chiba Y, et al. Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, Acutely Reduces Energy Expenditure in BAT via Neural Signals in Mice. PLoS One. 2016 Mar 10;11(3):e0150756.
Citations
1. Xuan M Y, Piao S G, Ding J, et al. Dapagliflozin Alleviates Renal Fibrosis by Inhibiting RIP1-RIP3-MLKL-Mediated Necroinflammation in Unilateral Ureteral Obstruction. Frontiers in pharmacology. 2021, 12 2. Ding L, Chen X, Zhang W, et al.Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling.The Journal of Clinical Investigation.2023, 133(1). 3. Huang H, Kung F L, Huang Y W, et al.Sensitization of cancer cells to paclitaxel-induced apoptosis by canagliflozin.Biochemical Pharmacology.2024: 116140.